Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03865979 · ClinicalTrials.gov registry record · NA
AI ENRICH - AI Detection of ICH
A NA study, sponsored by Viz.ai.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT03865979: Completed NA study, sponsored by Viz.ai.
NCT03865979 is a NA study that has completed, run by Viz.ai. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03865979, a NA study, has completed, sponsored by Viz.ai.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
To evaluate the performance of the Viz RECRUIT software in subjects identified as symptomatic of a stroke event as determined by standard of care imaging assessments and interpretation.
Primary Outcome
Rate of concordance of Viz RECRUIT software identification of ICH via Head CT images and standard of care radiologist identification of ICH.
Interventions
- DEVICE Viz RECRUIT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-01-23 |
| Est. Completion | 2023-04-28 |
| Phase | NA |
What the finished NCT03865979 record still lists
NCT03865979 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Viz RECRUIT is the first listed.
NCT03865979 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03865979 about?
NCT03865979 is a clinical study titled "AI ENRICH - AI Detection of ICH". To evaluate the performance of the Viz RECRUIT software in subjects identified as symptomatic of a stroke event as determined by standard of care imaging assessments and interpretation.
What is the current status of trial NCT03865979?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2020-01-23. Estimated completion is 2023-04-28.
What interventions are being tested in trial NCT03865979?
The interventions under investigation include: Viz RECRUIT (DEVICE).
Who is sponsoring clinical trial NCT03865979?
This trial is sponsored by Viz.ai, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03865979's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI